Impact of omalizumab on medical cost of childhood asthma in Japan

Omalizumab is effective in children with severe asthma, but its impact on medical cost in Japan is not clear. We evaluated the impact of omalizumab on medical cost by comparing the pre‐ vs post‐omalizumab‐initiation medical costs of 12 children with severe asthma who received omalizumab for 2 years,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pediatrics international 2016-05, Vol.58 (5), p.425-428
Hauptverfasser:	Yoshikawa, Hideki, Iwata, Mihoko, Matsuzaki, Hiroshi, Ono, Rintaro, Murakami, Yoko, Taba, Naohiko, Honjo, Satoshi, Motomura, Chikako, Odajima, Hiroshi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Anti-Asthmatic Agents - economics Anti-Asthmatic Agents - therapeutic use Asthma Asthma - drug therapy Asthma - economics Child Childhood Children Cost-Benefit Analysis Drug therapy Female Health Care Costs - statistics & numerical data Health care expenditures Hospitalization Hospitalization - economics Hospitalization - statistics & numerical data Humans Immunoglobulin E Immunotherapy Japan Male medical cost Monoclonal antibodies omalizumab Omalizumab - economics Omalizumab - therapeutic use Pediatrics Retrospective Studies Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!